Antiviral Drugs - Dominican Republic

The projected revenue for the Antiviral Drugs market in the Dominican Republic is expected to reach US$21.64m in 2024.
It is anticipated that the revenue will show an annual growth rate (CAGR 2024-2029) of 2.71%, leading to a market volume of US$24.74m by 2029.
When compared globally, United States is expected to generate the highest revenue, with an estimated amount of US$30.64bn in 2024.
The Dominican Republic has seen a surge in demand for antiviral drugs due to the increasing prevalence of viral infections in the country.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The Antiviral Drugs market in Dominican Republic has been growing steadily in recent years.

Customer preferences: The increasing prevalence of viral infections and the growing awareness of the importance of antiviral drugs in treating these infections have led to a rise in demand for these drugs in Dominican Republic. Customers are looking for effective and affordable antiviral drugs that can help them recover from viral infections quickly.

Trends in the market: One of the major trends in the Antiviral Drugs market in Dominican Republic is the increasing use of generic drugs. Generic drugs are becoming more popular among customers due to their affordable prices and similar efficacy to branded drugs. This has led to a rise in the number of generic drug manufacturers in the country.Another trend in the market is the increasing focus on research and development of new antiviral drugs. Many pharmaceutical companies are investing heavily in R&D to develop new drugs that can effectively treat viral infections. This has led to the introduction of several new antiviral drugs in the market in recent years.

Local special circumstances: Dominican Republic has a high prevalence of viral infections such as dengue fever, chikungunya, and Zika virus. This has led to a high demand for antiviral drugs in the country. In addition, the country has a large population of low-income individuals who cannot afford expensive branded drugs. This has led to a rise in demand for affordable generic drugs.

Underlying macroeconomic factors: The Antiviral Drugs market in Dominican Republic is influenced by several macroeconomic factors such as GDP growth, healthcare expenditure, and government policies. The country has been experiencing steady economic growth in recent years, which has led to an increase in healthcare expenditure. The government has also been taking steps to improve the healthcare infrastructure in the country, which has led to an increase in the availability of antiviral drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.